Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report
In conclusion, the combination of tislelizumab and anlotinib may offer a viable therapeutic option for recurrent metastatic BRCA2-mutated PDAC.PMID:38515651 | PMC:PMC10952340 | DOI:10.3892/etm.2024.12466 (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - March 22, 2024 Category: General Medicine Authors: Sujuan Peng Hongxiang Huang Xie Zhu Jinhong Chen Xinjing Ding Fen Wang Li Chen Zhihui Lu Source Type: research
The New WHO Category of "Molecularly Defined Renal Carcinomas": Clinical and Diagnostic Features and Management Implications
Urol Oncol. 2024 Mar 21:S1078-1439(24)00333-8. doi: 10.1016/j.urolonc.2024.02.003. Online ahead of print.ABSTRACTThe evolution of classification of renal tumors has been impacted since the turn of the millennium by rapid progress in histopathology, immunohistochemistry, and molecular genetics. Together, these features have enabled firm recognition of specific, classic types of renal cell carcinomas, such as clear cell renal cell carcinoma, that in current practice trigger histologic-type specific management and treatment protocols. Now, the fifth Edition World Health Classification's new category of "Molecularly defined re...
Source: Urologic Oncology - March 22, 2024 Category: Urology & Nephrology Authors: Jonathan Kanakaraj Justin Chang Lance J Hampton Steven Christopher Smith Source Type: research
Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review
Rapamycin, an established mTOR inhibitor in clinical practice, is widely recognized for its therapeutic efficacy. Ridaforolimus, a non-prodrug rapalog, offers improved aqueous solubility, stability, and affinity compared to rapamycin. In recent years, there has been a surge in clinical trials involving ridaforolimus. We searched PubMed for ridaforolimus over the past decade and selected clinical trials of ridaforolimus to make a summary of the research progress of ridaforolimus in clinical trials. The majority of these trials explored the application of ridaforolimus in treating various tumors, including endometrial cancer...
Source: Frontiers in Pharmacology - March 22, 2024 Category: Drugs & Pharmacology Source Type: research
Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma
ConclusionsUpregulated ANXA2 was associated with poor PFS and therapeutic resistance in RCC treated by IO + TKI therapy, and related with T cell exhaustion. The integrated RF score could stratify patients who would benefit from IO + TKI therapy. (Source: Hormones and Cancer)
Source: Hormones and Cancer - March 22, 2024 Category: Cancer & Oncology Source Type: research
Machine learning models for predicting the onset of chronic kidney disease after surgery in patients with renal cell carcinoma
Patients with renal cell carcinoma (RCC) have an elevated risk of chronic kidney disease (CKD) following nephrectomy. Therefore, continuous monitoring and subsequent interventions are necessary. It is recommen... (Source: BMC Medical Informatics and Decision Making)
Source: BMC Medical Informatics and Decision Making - March 22, 2024 Category: Information Technology Authors: Seol Whan Oh, Seok-Soo Byun, Jung Kwon Kim, Chang Wook Jeong, Cheol Kwak, Eu Chang Hwang, Seok Ho Kang, Jinsoo Chung, Yong-June Kim, Yun-Sok Ha and Sung-Hoo Hong Tags: Research Source Type: research
Memory/active T cell activation is associated with immunotherapeutic response in fumarate hydratase-deficient renal cell carcinoma
CONCLUSIONS: ICI plus TKI combination therapy may represent a promising treatment option for metastatic FH-deficient RCC. A memory/active T cell-derived signature is associated with the efficacy of ICI+TKI but necessitates further validation.PMID:38512114 | DOI:10.1158/1078-0432.CCR-23-2760 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 21, 2024 Category: Cancer & Oncology Authors: Junru Chen Xu Hu Junjie Zhao Xiaoxue Yin Linmao Zheng Jingjing Guo Jianhui Chen Yongquan Wang Xinan Sheng Haiying Dong Xiaodong Liu Xingming Zhang Jiayu Liang Haolin Liu Jin Yao Jiyan Liu Yali Shen Zhibin Chen Zhengyu He Yaodong Wang Ni Chen Ling Nie Meng Source Type: research
Memory/active T cell activation is associated with immunotherapeutic response in fumarate hydratase-deficient renal cell carcinoma
CONCLUSIONS: ICI plus TKI combination therapy may represent a promising treatment option for metastatic FH-deficient RCC. A memory/active T cell-derived signature is associated with the efficacy of ICI+TKI but necessitates further validation.PMID:38512114 | DOI:10.1158/1078-0432.CCR-23-2760 (Source: Cell Research)
Source: Cell Research - March 21, 2024 Category: Cytology Authors: Junru Chen Xu Hu Junjie Zhao Xiaoxue Yin Linmao Zheng Jingjing Guo Jianhui Chen Yongquan Wang Xinan Sheng Haiying Dong Xiaodong Liu Xingming Zhang Jiayu Liang Haolin Liu Jin Yao Jiyan Liu Yali Shen Zhibin Chen Zhengyu He Yaodong Wang Ni Chen Ling Nie Meng Source Type: research
Dexmedetomidine attenuates lipopolysaccharide-induced renal cell fibrotic phenotypic changes by inhibiting necroinflammation via activating α < sub > 2 < /sub > -adrenoceptor: A combined randomised animal and in vitro study
CONCLUSIONS: Dex reduced EMT following LPS stimulation whilst simultaneously inhibiting pyroptosis and necroptosis via α2-AR activation in the renal tubular cells. The "anti-fibrotic" and cytoprotective properties and its clinical use of Dex need to be further studied.PMID:38513598 | DOI:10.1016/j.biopha.2024.116462 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 21, 2024 Category: Drugs & Pharmacology Authors: Qizhe Sun Priyanka Kamath Yibing Sun Min Liang Lingzhi Wu Enqiang Chang Qian Chen Azeem Alam Yi Liu Hailin Zhao Daqing Ma Source Type: research
Dexmedetomidine attenuates lipopolysaccharide-induced renal cell fibrotic phenotypic changes by inhibiting necroinflammation via activating α < sub > 2 < /sub > -adrenoceptor: A combined randomised animal and in vitro study
CONCLUSIONS: Dex reduced EMT following LPS stimulation whilst simultaneously inhibiting pyroptosis and necroptosis via α2-AR activation in the renal tubular cells. The "anti-fibrotic" and cytoprotective properties and its clinical use of Dex need to be further studied.PMID:38513598 | DOI:10.1016/j.biopha.2024.116462 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 21, 2024 Category: Drugs & Pharmacology Authors: Qizhe Sun Priyanka Kamath Yibing Sun Min Liang Lingzhi Wu Enqiang Chang Qian Chen Azeem Alam Yi Liu Hailin Zhao Daqing Ma Source Type: research
Memory/active T cell activation is associated with immunotherapeutic response in fumarate hydratase-deficient renal cell carcinoma
CONCLUSIONS: ICI plus TKI combination therapy may represent a promising treatment option for metastatic FH-deficient RCC. A memory/active T cell-derived signature is associated with the efficacy of ICI+TKI but necessitates further validation.PMID:38512114 | DOI:10.1158/1078-0432.CCR-23-2760 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 21, 2024 Category: Cancer & Oncology Authors: Junru Chen Xu Hu Junjie Zhao Xiaoxue Yin Linmao Zheng Jingjing Guo Jianhui Chen Yongquan Wang Xinan Sheng Haiying Dong Xiaodong Liu Xingming Zhang Jiayu Liang Haolin Liu Jin Yao Jiyan Liu Yali Shen Zhibin Chen Zhengyu He Yaodong Wang Ni Chen Ling Nie Meng Source Type: research
Prognostic value of inflammation and immune-related gene NOD2 in clear cell renal cell carcinoma
In conclusion, NOD2 is a potential prognostic biomarker for ccRCC and the miR-20b-5p/NOD2/IL-8 axis may regulate in flammation- and immune-mediated tumorigenesis in ccRCC. (Source: Human Cell)
Source: Human Cell - March 21, 2024 Category: Cytology Source Type: research
Deep learning using contrast-enhanced ultrasound images to predict the nuclear grade of clear cell renal cell carcinoma
ConclusionThe deep learning model based on CEUS images can accurately differentiate between low-grade and high-grade ccRCC in a non-invasive manner. (Source: World Journal of Urology)
Source: World Journal of Urology - March 21, 2024 Category: Urology & Nephrology Source Type: research
Outcomes of Acute Ischemic Stroke Among Patients with Renal Cell Carcinoma: A Nationwide Analysis
Renal cell carcinoma (RCC) has been associated with an increased risk for acute ischemic stroke (AIS). As individuals with cancer who experience AIS tend to face higher mortality rates compared to AIS patients without cancer, recognizing the implications of RCC in AIS is crucial for identifying high-risk patients for major complications and directing management strategies. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - March 21, 2024 Category: Neurology Authors: Galadu Subah, Sabrina Zeller, Aarti Jain, Emma Bloom, Saya Mieth, Nimrod Gozum, Austin Li, Fangyi Lin, Anaz Uddin, Stuart Brill, Tarik Al-Bermani, Gurmeen Kaur, Chirag D. Gandhi, Fawaz Al-Mufti Source Type: research
Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma
AbstractRenal cell carcinoma originates from the lining of the proximal convoluted renal tubule and represents the most common type of kidney cancer. Risk factors and comorbidities might be associated to renal cell carcinoma, while a small fraction of 2 –3% emerges from patients with predisposing cancer syndromes, typically associated to hereditary mutations inVHL, folliculin, fumarate hydratase orMET genes. Here, we report a case of renal cell carcinoma in patient with concurrent germline mutations inBRCA1 andRAD51 genes. This case displays an unusual high mutational burden and chromosomal aberrations compared to the ty...
Source: Hormones and Cancer - March 21, 2024 Category: Cancer & Oncology Source Type: research
---
This issue on patent foramen ovale (PFO) is dedicated to my oncologist, Alexandra Drakaki, MD, and the researchers who developed immunotherapy. Without their support, I would not have been alive to help write and edit this compendium on PFO. I had a nephrectomy for renal cell carcinoma in April 2023 and began immunotherapy for metastatic disease in November 2023. I appreciate the opportunity I have been given to describe the research in this field over the past 25 years. (Source: Cardiology Clinics)
Source: Cardiology Clinics - March 21, 2024 Category: Cardiology Authors: Jonathan M. Tobis Tags: Dedication Source Type: research
